Malignant hyperthermia.
Malignant hyperthermia is a rare syndrome that occurs in genetically susceptible individuals who are exposed to frequently used inhalation anesthetics. The disorder is most common in children and young adults. It is triggered through a defect in the ability of skeletal muscles to concentrate and release calcium. Signs of malignant hyperthermia include hypercarbia, muscle rigidity and tachycardia. Temperature elevation is often a late sign of the syndrome. Treatment begins with stopping all inhaled anesthetics at the earliest sign of the syndrome. The use of dantrolene has significantly reduced mortality from malignant hyperthermia. No simple screening test exists. Family members or those with a suspicious history need to be counseled and should consider muscle biopsy and testing prior to surgery.
Moore
J L
JL
San Diego Sports Medicine Center, California.
Rice
E L
EL
D000328:Adult; D001706:Biopsy; D003620:Dantrolene / Q000627:therapeutic use; D005260:Female; D015277:Hotlines; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*
D003620:Dantrolene